Brief: Celltrion Announces U.S. Availability Of Avtozma® (Tocilizumab-Anoh) Subcutaneous (SC) Formulation
16/03/2026 12:16
March 16 (Reuters) - Celltrion Inc 068270.KS: CELLTRION ANNOUNCES U.S. AVAILABILITY OF AVTOZMA® (TOCILIZUMAB-ANOH) SUBCUTANEOUS (SC) FORMULATION Source text: ID:nPnb3W0S9a Further company coverage: 068270.KS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares